Summary

High Throughput Screening Market Research Report Market Forecast till 2030
Market Overview
High Throughput Screening Market is anticipated to register a significant CAGR of 9.70% during the forecast period.
The variables adding to the development of the market are the developing genomic research exercises, rising interest for customized medication, expanding interest in innovative work, and expanding mindfulness and reception.
The high-throughput screening market is encountering significant development because of the rising interest for customized medication. Customized medication, otherwise called accuracy medication, is an inventive methodology that thinks about a singular's exceptional hereditary cosmetics, way of life, and natural variables to tailor clinical medicines and mediations. High-throughput screening, with its capacity to succession enormous volumes of DNA or RNA quickly and cost-really, assumes a crucial part in the headway of customized medication. One of the essential drivers behind the rising interest for customized medication is the developing acknowledgment that people answer diversely to medicines because of their one-of-a-kind hereditary variety. High-throughput screening empowers the ID of sickness related hereditary variations and offers bits of knowledge into the hereditary variables fundamental the viability and security of explicit treatments. By breaking down a person's hereditary data, medical care experts can decide the most appropriate therapy choices and upgrade measurements, bringing about superior patient results.
Market Segment Insights
Based on product & service, the High Throughput Screening Market has been segmented into consumables, instruments, and software & services. Based on technology, the Market has classified into cell-based assays, Lab-on-a-Chip (LOC), ultra-high-throughput screening, label-free technology, and others.
Based on application, the High Throughput Screening Market has segmented into drug discovery, biochemical screening, cell & organ-based screening, and others. In terms of end user, the Market has categorized into pharmaceutical and biotechnology companies, research institutes and organizations, and contract research organizations.
Regional Insights
North America represented the biggest market portion of 42.96% in 2022 and Asia-Pacific is projected to develop at the highest CAGR of 11.01% during the figure time frame. Moreover, market development is driven by expanding clinical preliminary numbers across the globe, and developing exploration and improvement. In addition, the underneath diagram addresses the quantity of clinical preliminaries for every region began in 2022. The market development has been driven by inorganic procedures to extend high-throughput screening (HTS) answers for measure biochemical exercises and recognize restricting associations, which speed up the timetable and lessen expenses to distinguish lead drug competitors. For example, in January 2023, Charles Waterway Research Facilities Global, Inc. (US) procured SAMDI Tech, Inc. (US), a main supplier of HTS answers for grow HTS portfolio.
The development of the European high-throughput screening market is driven by elevating HTS undertakings to speed up the revelation of a lead particle for another medication. For example, in Walk 2023, SCREENTECH opened under the correlative arrangement for biotechnology in Catalonia (Spain). This drive focused on the advancement of new ventures in view of the medication screening and medication target connection examination stage at IRB Barcelona (US).
In addition, the high guilty pleasure of high-throughput screening fire up designers like CN Bio (UK), Evosep (Denmark), Ovizio (Belgium), and Oxford Nanopore Advancements plc. (UK) through raising financing and consolidating advancement is setting out enormous open doors for the region's development.

Major Players

Key Companies in the High Throughput Screening Market are Agilent Technologies Inc, Merck KGaA, Corning Incorporated, Tecan Trading AG, PerkinElmer Inc, Luminex Corporation, Beckman Coulter Inc, Hoffmann-La Roche Ltd, Promega Corporation, Hamilton Company, and Others.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING GENOMIC RESEARCH ACTIVITIES
4.2.2 RISING DEMAND FOR PERSONALIZED MEDICINE
4.2.3 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT
4.3 RESTRAINTS
4.3.1 HIGH INITIAL SETUP COSTS
4.4 OPPORTUNITY
4.4.1 INCREASING AWARENESS AND ADOPTION
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D & DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL HIGH THROUGHPUT SCREENING MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTION
5.3.3 IMPACT ON REGION
5.3.4 IMPACT ON PRICING
6 GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY PRODUCTS & SERVICES
6.1 OVERVIEW
6.2 CONSUMABLES
6.3 INSTRUMENTS
6.4 SOFTWARE & SERVICES
7 GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY TECHNOLOGY
7.1 OVERVIEW
7.2 CELL-BASED ASSAYS
7.2.1 3D CELL CULTURE
7.3 LAB-ON-A-CHIP (LOC)
7.4 ULTRA-HIGH-THROUGHPUT SCREENING
7.5 LABEL-FREE TECHNOLOGY
7.6 OTHERS
8 GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 DRUG DISCOVERY
8.3 BIOCHEMICAL SCREENING
8.4 CELL- & ORGAN-BASED SCREENING
8.5 OTHERS
9 GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY END USER
9.1 OVERVIEW
9.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
9.3 RESEARCH INSTITUTES AND ORGANISATIONS
9.4 CONTRACT RESEARCH ORGANIZATIONS
10 GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 UK
10.3.4 ITALY
10.3.5 SPAIN
10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 INDIA
10.4.4 SOUTH KOREA
10.4.5 AUSTRALIA
10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
10.5.1 MIDDLE EAST
10.5.2 AFRICA
10.5.3 LATIN AMERICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL HIGH THROUGHPUT SCREENING MARKET
11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL HIGH THROUGHPUT SCREENING MARKET
11.5 KEY DEVELOPMENT ANALYSIS
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT/COMPANY LAUNCH/PRODUCT APPROVAL
11.6.2 COLLABORATION/AGREEMENT
11.6.3 ACQUISITION/MERGER
11.7 FINANCIAL MATRIX
11.7.1 SALES (USD MILLION), 2022
11.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2022
12 COMPANY PROFILES
12.1 CORNING INCORPORATED
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 AGILENT TECHNOLOGIES, INC
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 KEY STRATEGIES
12.3 LUMINEX CORPORATION
12.3.1 COMPANY OVERVIEWS
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIES
12.4 F. HOFFMANN-LA ROCHE LTD
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 PROMEGA CORPORATION
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIES
12.6 MERCK KGAA
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 TECAN TRADING AG
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 PERKINELMER INC
12.8.1 COMPANY OVERVIEWS
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIES
12.9 BECKMAN COULTER, INC
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 HAMILTON COMPANY
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS